Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily

Journal of Clinical Investigation

Volumn 114, Issue 12, 2004, Pages 1741-1751

  Bierhaus, Angelika ^a   Haslbeck, Karl Matthias ^b   Humpert, Per M ^a   Liliensiek, Birgit ^a,c   Dehmer, Thomas ^d   Morcos, Michael ^a   Sayed, Ahmed A R ^a   Andrassy, Martin ^a,e   Schiekofer, Stephan ^a   Schneider, Jochen G ^a   Schulz, Jörg B ^d   Heuss, Dieter ^b   Neundörfer, Bernhard ^b   Dierl, Stefan ^f   Huber, Jochen ^f   Tritschler, Hans ^g   Schmidt, Ann Marie ^e   Schwaninger, Markus ^a   Haering, Hans Ulrich ^d   Schleicher, Erwin ^d   Kasper, Michael ^h   Stern, David M ⁱ   Arnold, Bernd ^c   Nawroth, Peter P ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^g Viatris Inc   (Germany)

^h DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

ⁱ MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; GLOBIN; IMMUNOGLOBULIN RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; RAGE PROTEIN, HUMAN; RAGE PROTEIN, MOUSE; TRANSCRIPTION FACTOR RELA; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE BIOPSY; NOCICEPTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SURAL NERVE; ANIMAL; BIOPSY; CYTOLOGY; DIABETIC NEPHROPATHY; DISEASE MODEL; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; PAIN; PAIN THRESHOLD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL GANGLION; TEMPERATURE; TIME; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; ANTIGENS, NEOPLASM; BIOPSY; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; FEMALE; GANGLIA, SPINAL; GLOBINS; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; LIGANDS; MALE; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PAIN; PAIN THRESHOLD; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TEMPERATURE; TIME FACTORS; TRANSCRIPTION FACTOR RELA; UP-REGULATION;

EID: 85047694774     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI18058     Document Type: Article

References (52)

1. Boulton, A.J. 1998. Lowering the risk of neuropathy, foot ulcers and amputations. Diabet. Med. 15(Suppl. 4):S57-S59.
2. Vinik, A.I., Park,T.S., Stansberry, K., and Pittenger, G.L. 2000. Diabetic neuropathies. Diabetologia. 43:957-973.
3. Greene, D.A., Stevens, M.J., Obrosova, I., and Feldman, E.L. 1999. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur. J. Pharmacol. 375:217-223.
4. Carrington, A.L., and Litchfield, J.E. 1999. The aldose reductase pathway and nonenzymatic glycation in the pathogenesis of diabetic neuropathy: a critical review for the end of the 20th Century. Diabetes Reviews. 7:275-299.
5. Ahlgren, S.C., and Levine, J.D. 1994. Protein kinase C inhibitors decrease hyperalgesia and C-fibre hyperexcitability in the streptozotocin- diabetic rat. J. Neurophysiol. 72:684-692.
6. Cameron, N.E., and Cotter, M.A. 1995. Neurovascular dysfunction in diabetic rats. J. Clin. Infest. 96:1159-1163.
7. Zochodne, D.W., and Cheng, C. 1999. Diabetic peripheral nerves are susceptible to multifocal ischemic damage from endothelin. Brain Res. 838:11-17.
8. Nagamatsu, M., et al. 1995. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 18:1160-1167.
9. Schratzberger, P., et al. 2001. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest. 107:1083-1092.
10. Hafer-Macko, C.E., Ivey, P.M., Gyure, K.A., Sorkin, J.D., and Macko, R.F. 2002. Thrombomodulin deficiency in human diabetic nerve microvasculature. Diabetes. 51:1957-1963.
11. Tomlinson, D.R., Fernyhough, P., and Diemel, L.T. 1996. Neurotropins and peripheral neuropathy. Philos. Trans. R. Soc. Land. B Biol. Sci. 351:455-462.
12. Sima, A.A., et al. 2001. C-peptide prevents and improves chronic type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia. 44:889-897.
13. Vlassara, H., Brownlee, M., and Cerami, A. 1981. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 78:5190-5192.
14. Haslbeck, K.M., et al. 2002. N(epsilon)-Carboxymethyllysine in diabetic and non-diabetic polyneuropathies. Acta Neuropathol. 104:45-52.
15. Sugimoto, K., Nizhizawa, Y., Horiuchi, S., and Yagihashi, S. 1997. Localization in human diabetic peripheral nerve of Nε-carboxymethyllysine- protein adducts, an advanced glycation endproduct. Diabetologia. 40:1380-1387.
16. Mattson, M.P., and Camandola, S. 2001. NF-κB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 107:247-254.
17. Okamoto, K., Martin, D.P., Schmelzer, J.D., Mitsui, Y., and Low, P.A. 2001. Pro- and antiinflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp. Neurol 169:386-391.
18. Vincent, A.M., Brownlee, M., and Russell, J.W. 2002. Oxidative stress and programmed cell death in diabetic neuropathy. Ann. N. Y. Acad. Sci. 959:368-383.
19. Bierhaus, A., et al. 1997. Advanced glycation end product-induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes. 46:1481-1490.
20. Hofmann, M.A., et al. 1999. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy demonstrate increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia. 42:222-232.
21. Haak, E.S., et al. 1999. The effect of alpha-lipoic acid on the neurovascular reflex in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc. Res. 58:28-34.
22. Ziegler, D., et al. 1999. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADlN III study). ALADlN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 22:1296-1301.
23. Ametov, A.S., et al. 2003. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 26:770-776.
24. Bierhaus, A., et al. 2001. Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes. 50:2792-2808.
25. Nishikawa, T., et al. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature. 404:787-790.
26. Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature. 414:813-820.
27. Schiekofer, S., et al. 2003. Acute (2h) hyperglycemic clamp causes intracellular formation of carboxymethyllysine, activation of Ras, p42/p44 MAPK and NF-κB in peripheral blood mononuclear cells. Diabetes. 52:621-633.
28. Li, J., and Schmidt, A.M. 1997. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272:16498-16506.
29. Schmidt, A.M., Yan, S.D., Yan, S.F., and Stern, D.M. 2001. The multiligand receptor RAGE is a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108:949-955. doi: 10.1172/ JCI200114002.
30. Poduslo, J.F., and Curran, G. 1992. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc. Natl. Acad. Sci. U. S. A. 89:2218-2222.
31. Constien, R., et al. 2001. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis. 30:36-44.
32. Gonzalez-Martinez, T., Perez-Pinera, P., Diaz-Esnal, B., and Vega, J.A. 2003. S-100 proteins in the human peripheral nervous system. Microsc. Res. Tech. 60:633-638.
33. Lernbecher, T., Muller, U., and Wirth, T. 1993. Distinct NF-kappa B/Rel transcription factors are responsible for tissue-specific and inducible gene activation. Nature. 365:767-770.
34. Barnes, P.J., and Karin, M. 1997. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1066-1071.
35. Flatters, S.J.L., Fox, A.J., and Dickenson, A.M. 2004. Nerve injury alters the effects of interleukin-6 on nociceptive transmission in peripheral afferents. Eur. J. Pharmacol. 484:183-191.
36. Liliensiek, B., et al. 2004. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113:1641-1650. doi:10.1172/JCI200418704.
37. ε-(carboxymethyl) lysine in human tissues in diabetes and aging. J. Clin. Invest. 99:457-468.
38. Menendez, L., Lastra, A., Hidaldo, A., and Baamonde, A. 2002. Unilateral hot plate test; a simple and sensitive method for detecting central and peripheral hyperalgesia in mice. J. Nettrosci. Methods. 113:91-97.
39. Chen, C.C., et al. 2002. A role for ASIC3 in the modulation of high intensity pain stimuli. Proc. Natl. Acad. Sci. U. S. A. 13:8992-8997.
40. Vinik, A.I., Erbas, T., Stansberry, K.B.,and Pittenger, G.L. 2001. Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp. Clin. Endocrinol. Diabetes. 109(Suppl. 2):S451-S473.
41. Kislinger, T., et al. 1999. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274:31740-31749.
42. Kislinger, T., et al. 2001. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol 21:905-910.
43. Lue, L.F., et al. 2001. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 171:29-45.
44. Lezoulac'h, F., Sagara, Y., Holsboer, F., and Behl, C. 1998. High constitutive NF-κB activation mediates resistance to oxidative stress in neuronal cells. J. Neurosci. 18:3224-3232.
45. Flynn, M.D., and Tooke, J.E. 1995. Diabetic neuropathy and the microcirculation. Diabet. Med. 12:298-301.
46. Yeh, C.H., et al. 2001. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes. 50:1495-1504.
47. Arancio, O., et al. 2004. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 23:4096-4105.
48. 1988. Consensus statement: report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care. 11:592-597.
49. Neundörfer, B. 1998. Klinik und Diagnose der Polyneuropathien. Dtsch. Med. Wochenschr. 23:1519-1522.
50. Dyck, P.J., Chance, P., Labedo, R., and Carney, J.A. 1993. Hereditary motor and sensory neuropathies. In Peripheral neuropathy. 3rd edition. P.J. Dyck et al., editors. W.B. Saunders Co. Philadephia, Pennsylvania, USA. 1094-1113.
51. Hounsom, L., Horrobin, D.F., Tritschler, H., Corder, R., and Tomlinson, D.R. 1998. α-Lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia. 41:839-843.
52. Stucky, C.L., and Lewin, G.L. 1999. Isolectin B 4-positive and -negative nociceptors are functionally distinct. J. Neurosci. 19:6497-6505.